| 166.8 -18.7 (-10.08%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 207.12 |
1-year : | 217.38 |
| Resists | First : | 177.33 |
Second : | 186.11 |
| Pivot price | 175.17 |
|||
| Supports | First : | 163.11 |
Second : | 135.71 |
| MAs | MA(5) : | 178.46 |
MA(20) : | 175.75 |
| MA(100) : | 151.28  |
MA(250) : | 144.23 |
|
| MACD | MACD : | 2.9 |
Signal : | 3.5 |
| %K %D | K(14,3) : | 62.6 |
D(3) : | 78.5 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 186.11 | Low : | 122.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NBIX ] has closed above bottom band by 6.5%. Bollinger Bands are 26.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 185.82 - 186.76 | 186.76 - 187.53 |
| Low: | 162.6 - 163.5 | 163.5 - 164.24 |
| Close: | 165.48 - 166.89 | 166.89 - 168.06 |
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Sat, 01 Aug 2026
Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand - Yahoo Finance
Sat, 01 Aug 2026
Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain? - Yahoo Finance
Sat, 01 Aug 2026
Neurocrine Biosciences (NBIX) Stock Slides As Growth Spending Steals Focus - simplywall.st
Fri, 31 Jul 2026
JPMorgan Chase & Co. Boosts Neurocrine Biosciences Inc (NBIX) St - GuruFocus
Fri, 31 Jul 2026
Neurocrine Biosciences, Inc. Stock 12‑Month Price Target Raised to $209.34, Implies 13% Upside - TradingView
Fri, 31 Jul 2026
Neurocrine Biosciences Inc (NBIX) Shares Fall 10.1% -- What GF S - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 9.93e+007 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 5,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 6.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 310.5 |
| Profit Margin | 21.5 % |
| Operating Margin | 22.8 % |
| Return on Assets (ttm) | 11.6 % |
| Return on Equity (ttm) | 22.5 % |
| Qtrly Rev. Growth | 42.2 % |
| Gross Profit (p.s.) | 5.12821e+009 |
| Sales Per Share | 7.94872e+009 |
| EBITDA (p.s.) | 2.12462e+009 |
| Qtrly Earnings Growth | 2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 864 (M) |
| PE Ratio | 25.66 |
| PEG Ratio | 0.4 |
| Price to Book value | 0.53 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.92 |
| Dividend | 0 |
| Forward Dividend | 5.33e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|